We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+132.32%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$742M
AUM Growth
+$199M
Cap. Flow
+$28.6M
Cap. Flow %
3.86%
Top 10 Hldgs %
43.53%
Holding
99
New
34
Increased
28
Reduced
16
Closed
17
Avg Time Held Equity + Options
3.4 quarters
Top 10 Avg Time Held Equity + Options
1.3 quarters
Top 20 Avg Time Held Equity + Options
2.7 quarters
Avg Time Held Equity only
3.8 quarters
Top 10 Avg Time Held Equity only
1.3 quarters
Top 20 Avg Time Held Equity only
2.8 quarters

Top Buys

Rank Stock Value
1
ABVX icon
Abivax
ABVX
+$33.1M
2
RNAM
Avidity Biosciences
RNAM
+$17.6M
3
DNTH icon
Dianthus Therapeutics
DNTH
+$14.8M
4
GUTS icon
Fractyl Health
GUTS
+$13.5M
5
BIIB icon
Biogen
BIIB
+$10.9M

Top Sells

Rank Stock Value
1
MRUS icon
Merus
MRUS
+$39M
2
VRNA
Verona Pharma
VRNA
+$33.9M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$20.5M
4
ETNB icon
89bio
ETNB
+$20M
5
SLNO icon
Soleno Therapeutics
SLNO
+$17.1M

Sector Composition

Rank Sector Weight
1 Healthcare 93.14%
2 Miscellaneous 6.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ABVX icon
1
Abivax
ABVX
$7.52B
$45.8M 6.18%
+539,704
New +$33.1M
2025 Q3
0 quarters
RYTM icon
2
Rhythm Pharmaceuticals
RYTM
$5.96B
$37.4M 5.04%
369,996
-30,776
-8% -$2.86M
2023 Q2
9 quarters
RNAM
3
DELISTED
Avidity Biosciences
RNAM
$36.8M 4.96%
844,633
+434,633
+106% +$17.6M
2024 Q1
6 quarters
NUVL icon
4
DELISTED
Nuvalent
NUVL
$32.2M 4.34%
372,300
+136,717
+58% +$10.8M
2023 Q4
7 quarters
URGN icon
5
UroGen Pharma
URGN
$1.87B
$31.5M 4.24%
1,577,283
-445,199
-22% -$7.99M
2023 Q3
8 quarters
AKRO icon
6
DELISTED
Akero Therapeutics
AKRO
$30.6M 4.12%
643,636
-70,175
-10% -$3.4M
2022 Q2
13 quarters
INSM icon
7
Insmed
INSM
$21.1B
$29.8M 4.01%
206,648
-42,412
-17% -$5.2M
2020 Q4
19 quarters
DNTH icon
8
Dianthus Therapeutics
DNTH
$4.34B
$26.6M 3.58%
674,966
+579,160
+605% +$14.8M
2025 Q1
2 quarters
QURE icon
9
uniQure
QURE
$1.48B
$26.6M 3.58%
455,000
+252,435
+125% +$4.58M
2024 Q4
3 quarters
CGON icon
10
CG Oncology
CGON
$5.53B
$25.7M 3.47%
638,346
+97,312
+18% +$2.83M
2025 Q2
1 quarter
UTHR icon
11
PUT
United Therapeutics
UTHR
$23.3B
$25.1M 3.39%
+59,900
New +$20.1M
2025 Q3
0 quarters
ORIC icon
12
Oric Pharmaceuticals
ORIC
$1.17B
$23.4M 3.15%
1,948,808
+147,979
+8% +$1.56M
2022 Q2
13 quarters
CDTX icon
13
DELISTED
Cidara Therapeutics
CDTX
$21.2M 2.85%
220,902
+116,959
+113% +$7.46M
2025 Q2
1 quarter
GUTS icon
14
Fractyl Health
GUTS
$53.4M
$16.9M 2.27%
883,333
+866,450
+5,132% +$13.5M
2024 Q1
6 quarters
KALV icon
15
DELISTED
KalVista Pharmaceuticals
KALV
$16.6M 2.24%
1,363,378
-468,793
-26% -$6.48M
2023 Q1
10 quarters
KOD icon
16
Kodiak Sciences
KOD
$5.76B
$16.4M 2.21%
1,000,000
+598,460
+149% +$5.16M
2023 Q3
8 quarters
RARE icon
17
CALL
Ultragenyx Pharmaceutical
RARE
$1.47B
$15.9M 2.14%
+528,200
New +$15.8M
2025 Q3
0 quarters
GOSS icon
18
Gossamer Bio
GOSS
$59.7M
$12.6M 1.69%
59,739
-4,596
-7% -$810K
2023 Q3
8 quarters
COGT icon
19
Cogent Biosciences
COGT
$4.87B
$11.7M 1.58%
+815,075
New +$9.66M
2025 Q3
0 quarters
CYTK icon
20
Cytokinetics
CYTK
$8.57B
$11.6M 1.56%
+211,000
New +$8.69M
2025 Q3
0 quarters
PCVX icon
21
Vaxcyte
PCVX
$10.5B
$11.3M 1.53%
314,339
+26,543
+9% +$879K
2025 Q2
1 quarter
BIIB icon
22
Biogen
BIIB
$33.8B
$11.3M 1.52%
+80,419
New +$10.9M
2025 Q3
0 quarters
ASND icon
23
Ascendis Pharma A/S
ASND
$14.7B
$10.6M 1.44%
53,554
-32,998
-38% -$6.15M
2024 Q3
4 quarters
CMPX icon
24
Compass Therapeutics
CMPX
$154M
$9.92M 1.34%
2,833,988
+1,584,207
+127% +$5M
2025 Q1
2 quarters
AMLX icon
25
Amylyx Pharmaceuticals
AMLX
$3.37B
$9.51M 1.28%
+700,000
New +$6.59M
2025 Q3
0 quarters
1
2 3 4

Similar funds

LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
PL
Parthenon LLC Louisville, Kentucky $962M AUM 27.46% 1-Year Est. Return
LAM
L2 Asset Management Wayland, Massachusetts $963M AUM 38.06% 1-Year Est. Return
ACP
Aviance Capital Partners Naples, Florida $963M AUM 32.56% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $964M AUM 2.51% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BEAM
Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return
RAM
Ramirez Asset Management New York $960M AUM 30.25% 1-Year Est. Return

Silverarc Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, Silverarc Capital Management held 99 positions worth $742M, up 37% from $542M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Silverarc Capital Management deployed $28.6M of net new capital in Q3 2025, opening 34 new positions and adding to 28 existing holdings. Its largest new stake was Abivax: 539,704 shares worth $45.8M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 90% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was UroGen Pharma, an estimated $7.99M trimmed.

  • Silverarc Capital Management's largest Q3 2025 buy was Abivax: 539,704 shares worth $45.8M.
  • Silverarc Capital Management added most to Avidity Biosciences in Q3 2025, an estimated $17.6M increase.
  • Silverarc Capital Management's biggest Q3 2025 reduction was UroGen Pharma, cutting an estimated $7.99M.
  • Silverarc Capital Management fully exited Merus in Q3 2025, selling an estimated $39M.
  • Silverarc Capital Management's ten largest holdings make up 44% of its $742M portfolio in Q3 2025.
  • Silverarc Capital Management opened 34 new positions and closed 17 in Q3 2025.
  • Silverarc Capital Management's portfolio value rose 37% quarter-over-quarter to $742M.

Based on Silverarc Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.